Press release - 10/04/2026 Lancet Countdown Europe: New Report on Health and Climate Change Europe’s dependence on fossil fuels is not only making the continent economically and politically vulnerable, it also has consequences for the population’s health. Growing air pollution, heat damage and the climate-related spread of infectious diseases are looming, warns the 2026 Europe Report of the Lancet Countdown on Health and Climate Change, which its co-directors are about to present to the public. https://www.gesundheitsindustrie-bw.de/en/article/press-release/lancet-countdown-europe-new-report-health-and-climate-change
Press release - 10/04/2026 New study identifies clinically relevant changes in airway wall thickness in COPD and at-risk individuals A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-study-identifies-clinically-relevant-changes-airway-wall-thickness-copd-and-risk-individuals
Press release - 10/04/2026 Vitamin B12 Found to Drive Inherited Behavioural Changes Across Generations A team of researchers from the Department of Integrative Evolutionary Biology at the Max Planck Institute for Biology Tübingen has discovered that vitamin B12 plays a key role in transmitting behavioural memories across generations. The study shows for the first time how a nutrient from the diet can, without altering the genome, influence behaviour over multiple generations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vitamin-b12-found-drive-inherited-behavioural-changes-across-generations
Press release - 10/04/2026 Molecular analyses could improve treatment options for a rare soft tissue tumor Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-analyses-could-improve-treatment-options-rare-soft-tissue-tumor
Photoimmunotherapy - 09/04/2026 Switching off tumours with light: how photons can be used to target prostate cancer Prostate cancer is the most common cancer among men in Germany. Relapses and the harsh side effects of traditional treatments remain a major challenge, even with advanced surgical techniques. At the University of Freiburg, Dr. Wolf is pioneering the development of photoimmunotherapy. Photoimmunotherapy combines light, antibodies and a specialised dye to precisely target tumour cells - simultaneously 'waking up' the immune system.https://www.gesundheitsindustrie-bw.de/en/article/news/switching-tumours-light-how-photons-can-be-used-target-prostate-cancer
Press release - 09/04/2026 “Positions, please!” For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.https://www.gesundheitsindustrie-bw.de/en/article/press-release/positions-please
Press release - 07/04/2026 No soft drink before the massage How does sugar affect relaxation exercises? A new study carried out by researchers from the University of Konstanz provides revealing insights into the connection between blood glucose and the autonomic nervous system: The intake of sugar counteracts relaxation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-soft-drink-massage
Press release - 07/04/2026 The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
Press release - 07/04/2026 The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
Press release - 02/04/2026 Pocket-sized biomedical technology to become smarter Volkswagen Foundation supports mobile health expert Professor Walter Karlen The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-biomedical-technology-become-smarter-volkswagen-foundation-supports-mobile-health-expert-professor-walter-karlen
Press release - 01/04/2026 Digital Assistance System Designed to Prevent Recurrent Heart Disease Women who have experienced a stroke or heart attack are at a higher risk of mortality than men. Fraunhofer researchers want to improve gender-specific aftercare with a customized assistance system – thus helping to prevent further heart disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-assistance-system-designed-prevent-recurrent-heart-disease
Press release - 31/03/2026 First steps towards cell therapy for brain disorders Researchers in Freiburg have found a way to selectively replace defective immune cells in the blood vessels of the brain using an animal model. This is an important first step towards cell therapies for Alzheimer’s disease and other brain disorders. The findings were recently published in the journal Nature Immunology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-steps-towards-cell-therapy-brain-disorders
Press release - 30/03/2026 Ulm University funds projects on molecular quantum bits and digital diabetes research Research incubators focus on ideas outside the mainstream Creating scope for innovative projects from various disciplines: That is the aim of the research incubators at Ulm University. The aim is to initiate developments and ideas that could become relevant research areas for the University. In the current call for proposals, the jury has selected two interdisciplinary projects on quantum chemistry and digital, sensor-based diabetes research. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulm-university-funds-projects-molecular-quantum-bits-and-digital-diabetes-research-research-incubators-focus-ideas-outside-mains
Event - 06/05/2025 Symposium of the Biological Development Center - Accelerating Translation from Discovery to Application Reutlingen, Informationsveranstaltung https://www.gesundheitsindustrie-bw.de/en/event/symposium-biological-development-center-accelerating-translation-discovery-application
Proof-of-concept study of organoid technology - 26/03/2026 Can organoids improve the treatment of pancreatic cancer? A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.https://www.gesundheitsindustrie-bw.de/en/article/news/can-organoids-improve-treatment-pancreatic-cancer
Press release - 25/03/2026 The Influence of Lymph Node Architecture on Lymphoma For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/influence-lymph-node-architecture-lymphoma
Press release - 24/03/2026 Ovarian Cancer: Adipose Tissue Influences the Efficacy of Immunotherapy In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eierstockkrebs-fettgewebe-beeinflusst-wirksamkeit-der-immuntherapie
Press release - 23/03/2026 Aggravated neuroimmune response, delayed wound healing Transcription factor NF-κB in astrocytes critically affects the outcome of traumatic brain injury (TBI) Traumatic brain injuries often lead to complications with long-lasting consequences on memory, concentration and movement control. Detrimental secondary inflammatory reactions at the injured tissue sites are often responsible for this. Researchers from Ulm have now shown that a transcription factor plays a key role in reactions to TBI. When this gene regulator is activated, an elevated neuroimmune response promotes inflammation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/aggravated-neuroimmune-response-delayed-wound-healing-transcription-factor-nf-kb-astrocytes-critically-affects-outcome-traumatic
Press release - 23/03/2026 After a Heart Attack: Inflammation Weakens the Heart’s Energy Production Why does heart function often continue to deteriorate after a heart attack, even though blood flow has been restored? A research team from the DZHK sites Heidelberg and North has now identified an important mechanism: an inflammatory switch in cardiomyocytes can impair cellular energy production and thereby drive the development of heart failure. The results were published in Nature Communications.https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-heart-attack-inflammation-weakens-hearts-energy-production
Press release - 23/03/2026 New findings on the first steps in Protein Synthesis In the earliest phase of creating human proteins, the protein complex NAC performs an essential task by starting the first steps towards folding proteins into their correct three-dimensional structures. This discovery was made by an international research team led by scientists from the Center for Molecular Biology of Heidelberg University. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-first-steps-protein-synthesis
Press release - 19/03/2026 New Approaches for Treatment-Resistant Disorders The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-treatment-resistant-disorders
Press release - 19/03/2026 Carl-Zeiss-Stiftung Funds Pioneering AI Project at the DKFZ How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-stiftung-funds-pioneering-ai-project-dkfz
Press release - 19/03/2026 How old are we really? Ageing is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a method that uses biomarkers to determine a person's biological age – a valuable tool for research on ageing and the development of new approaches in preventive medicine.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-old-are-we-really
Press release - 19/03/2026 Psilocybin combined with psychotherapy shows significant efficacy in treatment-resistant depression The results of the EPIsoDE study show that psilocybin can have a significant antidepressant effect. It is important that its use be integrated into psychotherapeutic pre- and post-treatment care. https://www.gesundheitsindustrie-bw.de/en/article/press-release/psilocybin-combined-psychotherapy-shows-significant-efficacy-treatment-resistant-depression
Press release - 17/03/2026 Targeting Cancer Drugs More Effectively: First EU Project Integrates Pharmacogenomics into Tumor Boards The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-cancer-drugs-more-effectively-first-eu-project-integrates-pharmacogenomics-tumor-boards